Top

Published in:

Open Access 01-12-2020 | Glioma | Review

FGFR- gene family alterations in low-grade neuroepithelial tumors

Author: Tejus A. Bale

Published in: Acta Neuropathologica Communications | Issue 1/2020

Abstract

The discovery of fibroblast growth factor receptor (FGFR) gene family alterations as drivers of primary brain tumors has generated significant excitement, both as potential therapeutic targets as well as defining hallmarks of histologic entities. However, FGFR alterations among neuroepithelial lesions are not restricted to high or low grade, nor to adult vs. pediatric-type tumors. While it may be tempting to consider FGFR-altered tumors as a unified group, this underlying heterogeneity poses diagnostic and interpretive challenges. Therefore, understanding the underlying biology of tumors harboring specific FGFR alterations is critical. In this review, recent evidence for recurrent FGFR alterations in histologically and biologically low-grade neuroepithelial tumors (LGNTs) is examined (namely FGFR1 tyrosine kinase domain duplication in low grade glioma, FGFR1-TACC1 fusions in extraventricular neurocytoma [EVN], and FGFR2-CTNNA3 fusions in polymorphous low-grade neuroepithelial tumor of the young [PLNTY]). Additionally, FGFR alterations with less well-defined prognostic implications are considered (FGFR3-TACC3 fusions, FGFR1 hotspot mutations). Finally, a framework for practical interpretation of FGFR alterations in low grade glial/glioneuronal tumors is proposed.

Allinson KS, O'Donovan DG, Jena R, Cross JJ, Santarius TS (2015) Rosette-forming glioneuronal tumor with dissemination throughout the ventricular system: a case report. Clin Neuropathol 34:64–69PubMedCrossRef

Anan M, Inoue R, Ishii K, Abe T, Fujiki M, Kobayashi H, Goya T, Nakazato Y (2009) A rosette-forming glioneuronal tumor of the spinal cord: the first case of a rosette-forming glioneuronal tumor originating from the spinal cord. Hum Pathol 40:898–901PubMedCrossRef

Ballester LY, Penas-Prado M, Leeds NE, Huse JT, Fuller GN (2018) FGFR1 tyrosine kinase domain duplication in pilocytic astrocytoma with anaplasia. Cold Spring Harb Mol Case Stud 4:a002378PubMedPubMedCentralCrossRef

Becker AP, Scapulatempo-Neto C, Carloni AC, Paulino A, Sheren J, Aisner DL, Musselwhite E, Clara C, Machado HR, Oliveira RS et al (2015) KIAA1549: BRAF gene fusion and FGFR1 hotspot mutations are prognostic factors in pilocytic astrocytomas. J Neuropathol Exp Neurol 74:743–754PubMedCrossRef

Becker D, Lee PL, Rodeck U, Herlyn M (1992) Inhibition of the fibroblast growth factor receptor 1 (FGFR-1) gene in human melanocytes and malignant melanomas leads to inhibition of proliferation and signs indicative of differentiation. Oncogene 7:2303–2313PubMed

Bennett JT, Tan TY, Alcantara D, Tetrault M, Timms AE, Jensen D, Collins S, Nowaczyk MJM, Lindhurst MJ, Christensen KM et al (2016) Mosaic activating mutations in FGFR1 cause encephalocraniocutaneous lipomatosis. Am J Hum Genet 98:579–587PubMedPubMedCentralCrossRef

Bielle F, Di Stefano AL, Meyronet D, Picca A, Villa C, Bernier M, Schmitt Y, Giry M, Rousseau A, Figarella-Branger D et al (2018) Diffuse gliomas with FGFR3-TACC3 fusion have characteristic histopathological and molecular features. Brain Pathol 28:674–683CrossRefPubMed

Bieser S, Reis M, Guzman M, Gauvain K, Elbabaa S, Braddock SR, Abdel-Baki MS (2015) Grade II pilocytic astrocytoma in a 3-month-old patient with encephalocraniocutaneous lipomatosis (ECCL): case report and literature review of low grade gliomas in ECCL. Am J Med Genet A 167A:878–881. https://doi.org/10.1002/ajmg.a.37017 CrossRefPubMed

Bitar M, Danish SF, Rosenblum MK (2018) A newly diagnosed case of polymorphous low-grade neuroepithelial tumor of the young. Clin Neuropathol 37:178–181PubMedPubMedCentralCrossRef

10.

Blumcke I, Aronica E, Urbach H, Alexopoulos A, Gonzalez-Martinez JA (2014) A neuropathology-based approach to epilepsy surgery in brain tumors and proposal for a new terminology use for long-term epilepsy-associated brain tumors. Acta Neuropathol 128:39–54PubMedPubMedCentralCrossRef

11.

Brat DJ, Scheithauer BW, Eberhart CG, Burger PC (2001) Extraventricular neurocytomas: pathologic features and clinical outcome. Am J Surg Pathol 25:1252–1260CrossRefPubMed

12.

Cancer Genome Atlas Research N (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061–1068CrossRef

13.

Chae YK, Ranganath K, Hammerman PS, Vaklavas C, Mohindra N, Kalyan A, Matsangou M, Costa R, Carneiro B, Villaflor VM et al (2017) Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application. Oncotarget 8:16052–16074PubMed

14.

Chen Y, Li X, Eswarakumar VP, Seger R, Lonai P (2000) Fibroblast growth factor (FGF) signaling through PI 3-kinase and Akt/PKB is required for embryoid body differentiation. Oncogene 19:3750–3756CrossRefPubMed

15.

Churi CR, Shroff R, Wang Y, Rashid A, Kang HC, Weatherly J, Zuo M, Zinner R, Hong D, Meric-Bernstam F et al (2014) Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One 9:e115383PubMedPubMedCentralCrossRef

16.

Darwis NDM, Nachankar A, Sasaki Y, Matsui T, Noda SE, Murata K, Tamaki T, Ando K, Okonogi N, Shiba S et al (2019) FGFR signaling as a candidate therapeutic target for cancers resistant to carbon ion radiotherapy. Int J Mol Sci 20:4563PubMedCentralCrossRef

17.

Deng MY, Sill M, Chiang J, Schittenhelm J, Ebinger M, Schuhmann MU, Monoranu CM, Milde T, Wittmann A, Hartmann C et al (2018) Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features. Acta Neuropathol 136:239–253CrossRefPubMed

18.

Di Stefano AL, Fucci A, Frattini V, Labussiere M, Mokhtari K, Zoppoli P, Marie Y, Bruno A, Boisselier B, Giry M et al (2015) Detection, characterization, and inhibition of FGFR-TACC fusions in IDH wild-type glioma. Clin Cancer Res 21:3307–3317PubMedPubMedCentralCrossRef

19.

Dieci MV, Arnedos M, Andre F, Soria JC (2013) Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov 3:264–279CrossRefPubMed

20.

Doherty P, Walsh FS (1996) CAM-FGF receptor interactions: a model for axonal growth. Mol Cell Neurosci 8:99–111CrossRefPubMed

21.

Duncan CG, Killela PJ, Payne CA, Lampson B, Chen WC, Liu J, Solomon D, Waldman T, Towers AJ, Gregory SG et al (2010) Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes. Oncotarget 1:265–277PubMedPubMedCentralCrossRef

22.

Ellison DW, Hawkins C, Jones DTW, Onar-Thomas A, Pfister SM, Reifenberger G, Louis DN (2019) cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAF(V600E) mutation. Acta Neuropathol 137:683–687CrossRefPubMed

23.

Fina F, Barets D, Colin C, Bouvier C, Padovani L, Nanni-Metellus I, Ouafik L, Scavarda D, Korshunov A, Jones DT et al (2017) Droplet digital PCR is a powerful technique to demonstrate frequent FGFR1 duplication in dysembryoplastic neuroepithelial tumors. Oncotarget 8:2104–2113CrossRefPubMed

24.

Frinchi M, Bonomo A, Trovato-Salinaro A, Condorelli DF, Fuxe K, Spampinato MG, Mudo G (2008) Fibroblast growth factor-2 and its receptor expression in proliferating precursor cells of the subventricular zone in the adult rat brain. Neurosci Lett 447:20–25CrossRefPubMed

25.

Furtado A, Arantes M, Silva R, Romao H, Resende M, Honavar M (2010) Comprehensive review of extraventricular neurocytoma with report of two cases, and comparison with central neurocytoma. Clin Neuropathol 29:134–140CrossRefPubMed

26.

Gessi M, Moneim YA, Hammes J, Goschzik T, Scholz M, Denkhaus D, Waha A, Pietsch T (2014) FGFR1 mutations in rosette-forming glioneuronal tumors of the fourth ventricle. J Neuropathol Exp Neurol 73:580–584CrossRefPubMed

27.

Granberg KJ, Annala M, Lehtinen B, Kesseli J, Haapasalo J, Ruusuvuori P, Yli-Harja O, Visakorpi T, Haapasalo H, Nykter M et al (2017) Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas. Neuro-Oncology 19:1206–1216PubMedPubMedCentral

28.

Greulich H, Pollock PM (2011) Targeting mutant fibroblast growth factor receptors in cancer. Trends Mol Med 17:283–292CrossRefPubMed

29.

Guerreiro Stucklin AS, Ryall S, Fukuoka K, Zapotocky M, Lassaletta A, Li C, Bridge T, Kim B, Arnoldo A, Kowalski PE et al (2019) Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas. Nat Commun 10:4343PubMedPubMedCentralCrossRef

30.

Guillemot F, Zimmer C (2011) From cradle to grave: the multiple roles of fibroblast growth factors in neural development. Neuron 71:574–588CrossRefPubMed

31.

Gupta VR, Giller C, Kolhe R, Forseen SE, Sharma S (2019) Polymorphous low-grade neuroepithelial tumor of the young: a case report with genomic findings. World Neurosurg 132:347–355CrossRefPubMed

32.

Hadari YR, Gotoh N, Kouhara H, Lax I, Schlessinger J (2001) Critical role for the docking-protein FRS2 alpha in FGF receptor-mediated signal transduction pathways. Proc Natl Acad Sci U S A 98:8578–8583PubMedPubMedCentralCrossRef

33.

Halfpenny A, Ferris SP, Grafe M, Woltjer R, Selden N, Nazemi K, Perry A, Solomon DA, Gultekin SH, Moore S et al (2019) A case of recurrent epilepsy-associated rosette-forming glioneuronal tumor with anaplastic transformation in the absence of therapy. Neuropathology 39:389–393PubMedPubMedCentralCrossRef

34.

Hart KC, Robertson SC, Kanemitsu MY, Meyer AN, Tynan JA, Donoghue DJ (2000) Transformation and stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene 19:3309–3320CrossRefPubMed

35.

Helsten T, Elkin S, Arthur E, Tomson BN, Carter J, Kurzrock R (2016) The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing. Clin Cancer Res 22:259–267CrossRefPubMed

36.

Hood FE, Royle SJ (2011) Pulling it together: the mitotic function of TACC3. Bioarchitecture 1:105–109PubMedPubMedCentralCrossRef

37.

Huse JT, Snuderl M, Jones DT, Brathwaite CD, Altman N, Lavi E, Saffery R, Sexton-Oates A, Blumcke I, Capper D et al (2017) Polymorphous low-grade neuroepithelial tumor of the young (PLNTY): an epileptogenic neoplasm with oligodendroglioma-like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathway. Acta Neuropathol 133:417–429CrossRefPubMed

38.

Johnson A, Severson E, Gay L, Vergilio JA, Elvin J, Suh J, Daniel S, Covert M, Frampton GM, Hsu S et al (2017) Comprehensive genomic profiling of 282 pediatric low- and high-grade gliomas reveals genomic drivers, tumor mutational burden, and hypermutation signatures. Oncologist 22:1478–1490PubMedPubMedCentralCrossRef

39.

Johnson DR, Giannini C, Jenkins RB, Kim DK, Kaufmann TJ (2019) Plenty of calcification: imaging characterization of polymorphous low-grade neuroepithelial tumor of the young. Neuroradiology 61:1327–1332CrossRefPubMed

40.

Jones DT, Hutter B, Jager N, Korshunov A, Kool M, Warnatz HJ, Zichner T, Lambert SR, Ryzhova M, Quang DA et al (2013) Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet 45:927–932PubMedPubMedCentralCrossRef

41.

Kane AJ, Sughrue ME, Rutkowski MJ, Aranda D, Mills SA, Lehil M, Fang S, Parsa AT (2012) Atypia predicting prognosis for intracranial extraventricular neurocytomas. J Neurosurg 116:349–354CrossRefPubMed

42.

Kocak O, Yarar C, Carman KB (2016) Encephalocraniocutaneous lipomatosis, a rare neurocutaneous disorder: report of additional three cases. Childs Nerv Syst 32:559–562CrossRefPubMed

43.

Kouhara H, Hadari YR, Spivak-Kroizman T, Schilling J, Bar-Sagi D, Lax I, Schlessinger J (1997) A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway. Cell 89:693–702CrossRefPubMed

44.

Lasorella A, Sanson M, Iavarone A (2017) FGFR-TACC gene fusions in human glioma. Neuro-Oncology 19:475–483PubMed

45.

LaVallee TM, Prudovsky IA, McMahon GA, Hu X, Maciag T (1998) Activation of the MAP kinase pathway by FGF-1 correlates with cell proliferation induction while activation of the Src pathway correlates with migration. J Cell Biol 141:1647–1658PubMedPubMedCentralCrossRef

46.

Lew ED, Furdui CM, Anderson KS, Schlessinger J (2009) The precise sequence of FGF receptor autophosphorylation is kinetically driven and is disrupted by oncogenic mutations. Sci Signal 2:ra6PubMedPubMedCentralCrossRef

47.

Li M, Bernard O (1992) FDC-P1 myeloid cells engineered to express fibroblast growth factor receptor 1 proliferate and differentiate in the presence of fibroblast growth factor and heparin. Proc Natl Acad Sci U S A 89:3315–3319PubMedPubMedCentralCrossRef

48.

Marseglia G, Lodola A, Mor M, Castelli R (2019) Fibroblast growth factor receptor inhibitors: patent review (2015-2019). Expert Opin Ther Pat 29:965–977CrossRefPubMed

49.

Nelson KN, Meyer AN, Siari A, Campos AR, Motamedchaboki K, Donoghue DJ (2016) Oncogenic gene fusion FGFR3-TACC3 is regulated by tyrosine phosphorylation. Mol Cancer Res 14:458–469CrossRefPubMed

50.

Parker BC, Annala MJ, Cogdell DE, Granberg KJ, Sun Y, Ji P, Li X, Gumin J, Zheng H, Hu L et al (2013) The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J Clin Invest 123:855–865PubMedPubMedCentral

51.

Patani H, Bunney TD, Thiyagarajan N, Norman RA, Ogg D, Breed J, Ashford P, Potterton A, Edwards M, Williams SV et al (2016) Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use. Oncotarget 7:24252–24268PubMedPubMedCentralCrossRef

52.

Pekmezci M, Villanueva-Meyer JE, Goode B, Van Ziffle J, Onodera C, Grenert JP, Bastian BC, Chamyan G, Maher OM, Khatib Z et al (2018) The genetic landscape of ganglioglioma. Acta Neuropathol Commun 6:47PubMedPubMedCentralCrossRef

53.

Peset I, Vernos I (2008) The TACC proteins: TACC-ling microtubule dynamics and centrosome function. Trends Cell Biol 18:379–388CrossRefPubMed

54.

Phi JH, Park SH, Chae JH, Wang KC, Cho BK, Kim SK (2010) Papillary glioneuronal tumor present in a patient with encephalocraniocutaneous lipomatosis: case report. Neurosurgery 67:E1165–E1169CrossRefPubMed

55.

Picca A, Berzero G, Bielle F, Touat M, Savatovsky J, Polivka M, Trisolini E, Meunier S, Schmitt Y, Idbaih A et al (2018) FGFR1 actionable mutations, molecular specificities, and outcome of adult midline gliomas. Neurology 90:e2086–e2094CrossRefPubMed

56.

Qaddoumi I, Orisme W, Wen J, Santiago T, Gupta K, Dalton JD, Tang B, Haupfear K, Punchihewa C, Easton J et al (2016) Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology. Acta Neuropathol 131:833–845PubMedPubMedCentralCrossRef

57.

Rand V, Huang J, Stockwell T, Ferriera S, Buzko O, Levy S, Busam D, Li K, Edwards JB, Eberhart C et al (2005) Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. Proc Natl Acad Sci U S A 102:14344–14349PubMedPubMedCentralCrossRef

58.

Rangarajan ES, Izard T (2013) Dimer asymmetry defines alpha-catenin interactions. Nat Struct Mol Biol 20:188–193PubMedPubMedCentralCrossRef

59.

Riva G, Cima L, Villanova M, Ghimenton C, Sina S, Riccioni L, Munari G, Fassan M, Giangaspero F, Eccher A (2018) Low-grade neuroepithelial tumor: unusual presentation in an adult without history of seizures. Neuropathology 38:557–560CrossRefPubMed

60.

Rivera B, Gayden T, Carrot-Zhang J, Nadaf J, Boshari T, Faury D, Zeinieh M, Blanc R, Burk DL, Fahiminiya S et al (2016) Germline and somatic FGFR1 abnormalities in dysembryoplastic neuroepithelial tumors. Acta Neuropathol 131:847–863PubMedPubMedCentralCrossRef

61.

Rodriguez EF, Scheithauer BW, Giannini C, Rynearson A, Cen L, Hoesley B, Gilmer-Flynn H, Sarkaria JN, Jenkins S, Long J et al (2011) PI3K/AKT pathway alterations are associated with clinically aggressive and histologically anaplastic subsets of pilocytic astrocytoma. Acta Neuropathol 121:407–420CrossRefPubMed

62.

Schlamann A, von Bueren AO, Hagel C, Zwiener I, Seidel C, Kortmann RD, Muller K (2014) An individual patient data meta-analysis on characteristics and outcome of patients with papillary glioneuronal tumor, rosette glioneuronal tumor with neuropil-like islands and rosette forming glioneuronal tumor of the fourth ventricle. PLoS One 9:e101211PubMedPubMedCentralCrossRef

63.

Schramm K, Iskar M, Statz B, Jager N, Haag D, Slabicki M, Pfister SM, Zapatka M, Gronych J, Jones DTW et al (2019) DECIPHER pooled shRNA library screen identifies PP2A and FGFR signaling as potential therapeutic targets for DIPGs. Neuro-Oncology 21:867CrossRefPubMedPubMedCentral

64.

Schubbert S, Shannon K, Bollag G (2007) Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 7:295–308CrossRefPubMed

65.

Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, Sturm D, Fontebasso AM, Quang DA, Tonjes M et al (2012) Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482:226–231PubMedCrossRef

66.

Sievers P, Appay R, Schrimpf D, Stichel D, Reuss DE, Wefers AK, Reinhardt A, Coras R, Ruf VC, Schmid S et al (2019) Rosette-forming glioneuronal tumors share a distinct DNA methylation profile and mutations in FGFR1, with recurrent co-mutation of PIK3CA and NF1. Acta Neuropathol 138:497–504CrossRefPubMed

67.

Sievers P, Stichel D, Schrimpf D, Sahm F, Koelsche C, Reuss DE, Wefers AK, Reinhardt A, Huang K, Ebrahimi A et al (2018) FGFR1:TACC1 fusion is a frequent event in molecularly defined extraventricular neurocytoma. Acta Neuropathol 136:293–302CrossRefPubMed

68.

Silveira L, DeWitt J, Thomas A, Tranmer B (2019) Disseminated rosette-forming glioneuronal tumor with spinal drop metastasis, a uniquely aggressive presentation of rare tumor. World Neurosurg 132:7–11CrossRefPubMed

69.

Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, Castano A, Liu EM, Reichel J, Porrati P, Pellegatta S et al (2012) Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 337:1231–1235PubMedPubMedCentralCrossRef

70.

Stransky N, Cerami E, Schalm S, Kim JL, Lengauer C (2014) The landscape of kinase fusions in cancer. Nat Commun 5:4846PubMedCrossRef

71.

Surrey LF, Jain P, Zhang B, Straka J, Zhao X, Harding BN, Resnick AC, Storm PB, Buccoliero AM, Genitori L et al (2019) Genomic analysis of dysembryoplastic neuroepithelial tumor spectrum reveals a diversity of molecular alterations dysregulating the MAPK and PI3K/mTOR pathways. J Neuropathol Exp Neurol 78:1100–1111PubMedCrossRef

72.

Tom MC, Cahill DP, Buckner JC, Dietrich J, Parsons MW, Yu JS (2019) Management for different glioma subtypes: are all low-grade gliomas created equal? Am Soc Clin Oncol Educ Book 39:133–145PubMedCrossRef

73.

Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, Lonigro RJ, Vats P, Wang R, Lin SF et al (2013) Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov 3:636–647PubMedPubMedCentralCrossRef

74.

Xu J, Yang Y, Liu Y, Wei M, Ren J, Chang Y, Huan Y, Yin H, Xue Y (2012) Rosette-forming glioneuronal tumor in the pineal gland and the third ventricle: a case with radiological and clinical implications. Quant Imaging Med Surg 2:227–231PubMedPubMedCentral

75.

Yao R, Natsume Y, Saiki Y, Shioya H, Takeuchi K, Yamori T, Toki H, Aoki I, Saga T, Noda T (2012) Disruption of Tacc3 function leads to in vivo tumor regression. Oncogene 31:135–148CrossRefPubMed

76.

Yoon K, Nery S, Rutlin ML, Radtke F, Fishell G, Gaiano N (2004) Fibroblast growth factor receptor signaling promotes radial glial identity and interacts with Notch1 signaling in telencephalic progenitors. J Neurosci 24:9497–9506PubMedPubMedCentralCrossRef

77.

Zhang J, Wu G, Miller CP, Tatevossian RG, Dalton JD, Tang B, Orisme W, Punchihewa C, Parker M, Qaddoumi I et al (2013) Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet 45:602–612PubMedPubMedCentralCrossRef

78.

Cosmic (Catalogue of Somatic Mutations in Cancer) (2019) Https://cancer.sanger.ac.uk/cosmic. Accessed 5 Dec 2019

Title: FGFR- gene family alterations in low-grade neuroepithelial tumors
Author: Tejus A. Bale
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Glioma
Glioma
Glioma
Brain Tumor
Astrocytoma
Astrocytoma
Astrocytoma
Published in: Acta Neuropathologica Communications / Issue 1/2020
Electronic ISSN: 2051-5960
DOI: https://doi.org/10.1186/s40478-020-00898-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

FGFR- gene family alterations in low-grade neuroepithelial tumors

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2020

A novel AFG3L2 mutation close to AAA domain leads to aberrant OMA1 and OPA1 processing in a family with optic atrophy

Regional correlation of biochemical measures of amyloid and tau phosphorylation in the brain

BCAS1-positive immature oligodendrocytes are affected by the α-synuclein-induced pathology of multiple system atrophy

Single-nucleus RNA-seq identifies Huntington disease astrocyte states

Adult onset pan-neuronal human tau tubulin kinase 1 expression causes severe cerebellar neurodegeneration in mice

Down syndrome cell adhesion molecule like-1 (DSCAML1) links the GABA system and seizure susceptibility